Agenus

Agenus Intangible Assets

The Intangible Assets of Agenus (AGEN) as of Oct 17, 2026 is 3.38 M USD. In the previous year, Intangible Assets was 4.41 M USD — a change of -23.46% (lower).

Intangible Assets

3.38 MUSD

YoY

-23.46%

Last updated:

Intangible Assets of Agenus is 2024 3.38 M USD. Intangible Assets of Agenus was 2023 4.41 M USD. It decreases by -23.46% lower compared to the previous year.

The Agenus Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
14.41 M USD
Jan 1, 2018
12.34 M USD
Jan 1, 2019
10.50 M USD
Jan 1, 2020
10.89 M USD
Jan 1, 2021
8.49 M USD
Jan 1, 2022
6.23 M USD
Jan 1, 2023
4.41 M USD
Jan 1, 2024
3.38 M USD
The Agenus Intangible Assets history
YEARIntangible AssetsYoY
3.38 MUSD-23.46%
4.41 MUSD-29.17%
6.23 MUSD-26.63%
8.49 MUSD-22.03%
10.89 MUSD+3.64%
10.50 MUSD-14.86%
12.34 MUSD-14.36%
14.41 MUSD-11.96%
16.37 MUSD-12.77%
18.76 MUSD+176.94%
6.77 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Agenus Stock analysis

What does Agenus do? Agenus Inc, listed under the ticker AGEN, is a biotechnology company based in Lexington, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Agenus Inc has a workforce of 81 employees. It went public through an IPO on February 4, 2000. The company's website is http://agenusbio.com/. Agenus Inc is engaged in the development of technologies aimed at treating cancers and infectious diseases. The company focuses on therapies that harness the immune system to combat cancer. Agenus Inc's activities include the development of antibody discovery platforms, such as Retrocyte Display, SECANT yeast display, and phage display technologies, which are used to create human antibodies. Additionally, the company is involved in the development of vaccine programs, including Prophage, AutoSynVax, and PhosPhoSynVax, as well as saponin-based vaccine adjuvants, notably QS-21 Stimulon. The company's discovery pipeline features checkpoint modulating (CPM) antibodies. Agenus Inc also works with heat shock protein (HSP)-based Prophage vaccine candidates and synthetic vaccine candidates, such as ASV and PSV. The company's headquarters are located in Lexington, Massachusetts, and it maintains a focus on advancing immuno-oncology research and development. Agenus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Agenus stock

Intangible Assets of Agenus is 3.38 M USD in 2024.

Intangible Assets of Agenus changed from 4.41 M USD to 3.38 M USD, representing a -23.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Agenus since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Agenus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Agenus

All Key Metrics — Agenus